NIST has awarded a contract for the quality assurance of 3D printed medications.


InfraTrac, a Maryland-based company specializing in quality assurance solutions for 3D printed products, has been granted a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Standards and Technology (NIST). The grant will support the development and commercialization of InfraTrac’s near-infrared (NIR) spectroscopy device.

InfraTrac recently completed Phase I of the contract, which demonstrated the device’s effectiveness in ensuring the accuracy of locally-produced 3D printed medication. The Phase II project aims to utilize NIR technology to detect incorrect drugs, improper dosage, faulty combinations, and failed prints. To verify the device’s efficacy, InfraTrac is collaborating with FabRx, a UK company that manufactures the M3DIMAKER 1 printer.

The M3DIMAKER 1 printer offers three different printheads, allowing InfraTrac to test the NIR spectroscopy device’s compatibility with various feedstocks and printing techniques. This versatility is crucial in developing a product that can be widely used in different pharmaceutical production environments.

In a press release, Sharon Flank, InfraTrac’s founder and CEO, expressed gratitude for NIST’s support and highlighted the company’s commitment to improving quality controls in 3D printed drug production. Flank also mentioned plans to expand collaboration with the University of Maryland’s School of Pharmacy.

This development signifies the commercialization of additive technologies in the pharmaceutical industry. The ability to produce drugs on-site has long been considered a potential advantage of additive manufacturing. However, currently, only ZipDose, a 3D printed drug with FDA approval, is available on the market, and on-site drug printing is limited to specific instances around the world.

The deployment of 3D printing technology on a larger scale raises questions about supply chains and the potential impact on traditional manufacturing processes. InfraTrac’s focus on quality assurance is crucial in ensuring the safe and widespread adoption of 3D printed drugs.

The company’s collaboration with NIST demonstrates the increasing technological maturity of the additive manufacturing sector. As the market continues to evolve, staying informed about the latest news and developments in the 3D printing industry is essential. By staying up-to-date, individuals and businesses can access valuable information and offers from third-party vendors.

Original source


“Why did the 3D printer go to therapy? Because it had too many layers of unresolved issues!”

Like it? Share with your friends!


Meet the mastermind behind GCode-Guru, a 3D printing wizard whose filament collection rivals their sock drawer. Here to demystify 3D tech with a mix of expert advice, epic fails, and espresso-fueled rants. If you've ever wondered how to print your way out of a paper bag (or into a new coffee cup), you're in the right place. Dive into the world of 3D printing with us—where the only thing more abundant than our prints is our sarcasm.


Your email address will not be published. Required fields are marked *

Choose A Format
Personality quiz
Series of questions that intends to reveal something about the personality
Trivia quiz
Series of questions with right and wrong answers that intends to check knowledge
Voting to make decisions or determine opinions
Formatted Text with Embeds and Visuals
The Classic Internet Listicles
The Classic Internet Countdowns
Open List
Submit your own item and vote up for the best submission
Ranked List
Upvote or downvote to decide the best list item
Upload your own images to make custom memes
Youtube and Vimeo Embeds
Soundcloud or Mixcloud Embeds
Photo or GIF
GIF format